Ohio Sen. Michael J. Skindell (D-23) introduced S.B. 79, legislation which would require pharmaceutical manufacturers and labelers to annually report "the value, nature, and purpose of any gift, fee, payment, subsidy, or other economic benefit provided in connection with detailing, promotion, or other marketing activities by the manufacturer or labeler, directly or through a marketer, to any licensed health professional authorized to prescribe drugs, hospital, nursing home, residential care facility, adult care facility, pharmacist, or health benefit plan administrator."

Subsection (E) would exempt "Any gift, fee, payment, subsidy, or other economic benefit the value of which does not exceed twenty-five dollars" and reasonable compensation and reimbursement for bona fide clinical trial work.

The bill is not likely to pass as currently constituted, since it is duplicative of the federal Physician Payments Sunshine Act.

However, given that incentives for health care professionals participating in marketing research studies could be inadvertently included, MRA will seek to amend or defeat S.B. 79.